trans-golgi network vesicle protein 23 homolog AGenealiases: FAM18A · YDR084C
Q-omics provides the consensus-scored TVP23A profile across patient tissues and cancer cell-line models. TVP23A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TVP23A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TVP23A RNA expression shows 17,909 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where TVP23A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TVP23A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TVP23A survival associations across molecular data types. TVP23A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TVP23A RNA expression–survival associations across cancer types. High TVP23A expression shows favorable associations in HNSC, SKCM, BLCA, BRCA, DLBC and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TVP23A RNA expression.
This table summarizes TVP23A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TVP23A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TVP23A shows lower tumor expression in LUSC, THCA, KICH, UCEC and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher TVP23A RNA expression in tumor versus normal tissue (log2 FC = +0.457, t-test p < 0.001).
This table shows molecular features associated with TVP23A in patient tissues and cancer cell lines. In patient samples, TVP23A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TVP23A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
